Large Cap Biotech Stocks to Buy Leading the Comeback Rally

Print Email

After two years of dominant performance in 2012 and 2013, the biotech rally hit a wall in late February, and the top stocks got absolutely hammered. Immediately, the bears jumped on the wounded sector leaders, saying they were way overvalued. Bulls argued, especially after the stocks were quickly eviscerated up to 20% and more, that forward earnings had them cheaper than some large pharmaceutical stocks, with much bigger growth potential.

A new research note from Credit Suisse maintains that the top large cap biotech leaders are leading the comeback rally from the hard sell-off. Plus, the analysts cite certain top names as not exactly having acquired, but are close to what they term, “domain domination.” Here are the top large cap biotech stocks to buy rated Outperform at Credit Suisse.

Biogen Idec Inc. (NASDAQ: BIIB) is one of top stocks to buy at Credit Suisse and on Wall Street. The company is one of those that Credit Suisse sees close to domain domination status. Many predict that Biogen’s Tysabri earnings will have a meaningful jump this year and beyond. Wall Street analysts also expect the company to reiterate guidance for anti-LINGO data in acute optic neuritis in the second half of this year, which provides the highest level of potential upside to Biogen’s share price if the results are positive. Investors can also look forward to a Prescription Drug User Fee Act (PDUFA) announcement on June 20 for the company’s hemophilia factor 8 Eloctate. The Credit Suisse price target for the biotech giant is at $400. The Thomson/First Call consensus figure is at $348.70. Biogen closed Friday at $317.55 a share.

ALSO READ: Weak Trading and Lower Investment Banking Revenues May Hurt These Banks

Celgene Corp. (NASDAQ: CELG) is probably the most prominent name of the companies we cover looking for a pancreatic cancer cure, and another stock Credit Suisse calls on the path to domain domination. For investors, it also may represent the best idea from a risk tolerance standpoint, as it has a strong product lineup and a stellar pipeline. Wall Street reports that physicians are very positive on Abraxane in combination with gemcitabine as new standard of care in first line patient treatment. They are also confident adding Abraxane improves outcomes. With very solid reimbursement levels for patients, most physicians haven’t considered an alternative, which would be generic paclitaxel. Wall Street analysts think that current use is about 35% of first line treatments, and they believe in three to five years that number could rise to 50% to 60% share. The Credit Suisse price target for this biotech powerhouse rated Outperform is $210, and the consensus estimate is pegged at $191.23. Celgene closed Friday at $161.31.